{
  "symbol": "GTBP",
  "company_name": "GT Biopharma Inc",
  "ir_website": "http://www.gtbiopharma.com/investor-relations/",
  "structured_data": [
    {
      "section_name": "News & Media",
      "links": [
        {
          "title": "Press Releases",
          "url": "http://www.gtbiopharma.com/investors/news-events/press-releases",
          "content": "Nasdaq: GTBP\n\n#  [![GT Biopharma, Inc.](https://d1io3yog0oux5.cloudfront.net/_2c702d37748ae5a37d1e29db3f20fa7d/gtbiopharma/files/images/header-logo.png)](/)\n\n## Press Releases\n\n  * [Home](/)\n  * [Investors](/investors)\n  * [News / Events](/investors/news-events)\n  * [Press Releases](https://ir.gtbiopharma.com/press-releases)\n\n\n\n# Press Releases\n\n  * [All News](https://ir.gtbiopharma.com/press-releases)\n  * [2024](https://ir.gtbiopharma.com/press-releases?year=2024)\n  * [2023](https://ir.gtbiopharma.com/press-releases?year=2023)\n  * [2022](https://ir.gtbiopharma.com/press-releases?year=2022)\n  * [2021](https://ir.gtbiopharma.com/press-releases?year=2021)\n  * [2020](https://ir.gtbiopharma.com/press-releases?year=2020)\n  * [2019](https://ir.gtbiopharma.com/press-releases?year=2019)\n  * [2018](https://ir.gtbiopharma.com/press-releases?year=2018)\n  * [2017](https://ir.gtbiopharma.com/press-releases?year=2017)\n\n## [GT Biopharma Reports Third Quarter 2024 Financial Results November 14, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/287/gt-biopharma-reports-third-quarter-2024-financial-results) ## [GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 26, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/286/gt-biopharma-to-participate-in-the-3rd-annual-roth) ## [GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 September 24, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/285/gt-biopharma-to-host-virtual-kol-event-showcasing-its-nk) ## [GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 14, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/284/gt-biopharma-reports-second-quarter-2024-financial-results) ## [GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia June 27, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/283/gt-biopharma-announces-fda-clearance-of-investigational-new) ## [GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 21, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/282/gt-biopharma-inc-announces-3-2-million-registered-direct) ## [GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/281/gt-biopharma-reports-first-quarter-2024-financial-results) ## [GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results March 26, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/280/gt-biopharma-reports-fourth-quarter-and-full-year-2023) ## [GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split February 1, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/279/gt-biopharma-inc-announces-1-for-30-reverse-stock-split) ## [Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders December 6, 2023 ](https://ir.gtbiopharma.com/press-releases/detail/278/leading-proxy-advisory-firms-iss-and-glass-lewis)\n\n[ ![RSS](https://ir.stockpr.com/sandlandwaste/images/rssfeed.gif) ](https://ir.gtbiopharma.com/news/rss)\n\n  * 1\n  * [2](https://ir.gtbiopharma.com/press-releases?page=2)\n  * [3](https://ir.gtbiopharma.com/press-releases?page=3)\n  * [4](https://ir.gtbiopharma.com/press-releases?page=4)\n  * [5](https://ir.gtbiopharma.com/press-releases?page=5)\n  * [6](https://ir.gtbiopharma.com/press-releases?page=6)\n  * [7](https://ir.gtbiopharma.com/press-releases?page=7)\n  * [8](https://ir.gtbiopharma.com/press-releases?page=8)\n  * [9](https://ir.gtbiopharma.com/press-releases?page=9)\n  * [10](https://ir.gtbiopharma.com/press-releases?page=10)\n  * [...19](https://ir.gtbiopharma.com/press-releases?page=19)\n  * [Next » ](https://ir.gtbiopharma.com/press-releases?page=2)\n\n\n"
        },
        {
          "title": "Important Information About Euronext Paris Listing",
          "url": "http://www.gtbiopharma.com/news-media/important-information-about-euronext-paris-listing",
          "content": "\n"
        },
        {
          "title": "Presentations",
          "url": "http://www.gtbiopharma.com/news-media/presentations",
          "content": "Nasdaq: GTBP\n\n#  [![GT Biopharma, Inc.](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/files/images/header-logo.png)](/)\n\n## Presentations\n\n  * [Home](/)\n  * [News & Media](/news-media)\n  * [Presentations](https://www.gtbiopharma.com/news-media/presentations)\n\n\n\n# Presentations\n\n## [Corporate Presentation November 19, 2024 ](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/db/184/702/pdf/GT+Biopharma+Corporate+Presentation+Nov+2024.pdf) ## [Virtual KOL Event Showcasing Webcast - Replay October 10, 2024 ](https://lifescievents.com/event/gtbiopharma/) ## [H.C. Wainwright Immune Cell Engager Conference Webcast - Replay August 17, 2023 ](https://journey.ct.events/view/ccbf62a5-4c3f-49ab-93a0-396a10afb3cb) ## [H.C. Wainwright Cell Therapy Virtual Conference Webcast - Replay February 28, 2023 ](https://journey.ct.events/view/05d12844-e346-409e-bc95-ac89157a9dd7) ## [Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) November 10, 2022 ](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/db/184/670/pdf/SITC+2022_Phung_eposter.pdf) ## [Tri-specific killer engagers target natural killer cells towards mesothelioma November 10, 2022 ](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/db/184/669/pdf/SITC2022_Felices_Poster.pdf) ## [H.C. Wainwright 24th Annual Global Investment Conference, September 12 – 14, 2022 Webcast – Replay September 15, 2022 ](https://journey.ct.events/view/7ef85275-0f6c-4f28-9723-80ab10b91207) ## [ESMO: B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells September 12, 2022 ](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/db/184/662/pdf/ESMO+GTB-5550+Poster+final+to+submit.pdf) ## [H.C. Wainwright Global Life Sciences Conference 2022 Webcast - Replay May 24, 2022 ](https://journey.ct.events/view/a27dc308-322b-40fb-91ff-13b4f09c9829) ## [AACR: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas April 9, 2022 ](https://d1io3yog0oux5.cloudfront.net/_cd3dba0c508cd7391d804babacac515a/gtbiopharma/db/184/649/pdf/MK_AACR_Poster.pdf)\n\n?>\n  * 1\n  * [2](https://www.gtbiopharma.com/news-media/presentations?page=2)\n  * [3](https://www.gtbiopharma.com/news-media/presentations?page=3)\n  * [Next » ](/news-media/presentations?page=2)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Investors",
      "links": [
        {
          "title": "Press Releases",
          "url": "http://www.gtbiopharma.com/investors/news-events/press-releases",
          "content": "Nasdaq: GTBP\n\n#  [![GT Biopharma, Inc.](https://d1io3yog0oux5.cloudfront.net/_2c702d37748ae5a37d1e29db3f20fa7d/gtbiopharma/files/images/header-logo.png)](/)\n\n## Press Releases\n\n  * [Home](/)\n  * [Investors](/investors)\n  * [News / Events](/investors/news-events)\n  * [Press Releases](https://ir.gtbiopharma.com/press-releases)\n\n\n\n# Press Releases\n\n  * [All News](https://ir.gtbiopharma.com/press-releases)\n  * [2024](https://ir.gtbiopharma.com/press-releases?year=2024)\n  * [2023](https://ir.gtbiopharma.com/press-releases?year=2023)\n  * [2022](https://ir.gtbiopharma.com/press-releases?year=2022)\n  * [2021](https://ir.gtbiopharma.com/press-releases?year=2021)\n  * [2020](https://ir.gtbiopharma.com/press-releases?year=2020)\n  * [2019](https://ir.gtbiopharma.com/press-releases?year=2019)\n  * [2018](https://ir.gtbiopharma.com/press-releases?year=2018)\n  * [2017](https://ir.gtbiopharma.com/press-releases?year=2017)\n\n## [GT Biopharma Reports Third Quarter 2024 Financial Results November 14, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/287/gt-biopharma-reports-third-quarter-2024-financial-results) ## [GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 26, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/286/gt-biopharma-to-participate-in-the-3rd-annual-roth) ## [GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 September 24, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/285/gt-biopharma-to-host-virtual-kol-event-showcasing-its-nk) ## [GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 14, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/284/gt-biopharma-reports-second-quarter-2024-financial-results) ## [GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia June 27, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/283/gt-biopharma-announces-fda-clearance-of-investigational-new) ## [GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 21, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/282/gt-biopharma-inc-announces-3-2-million-registered-direct) ## [GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/281/gt-biopharma-reports-first-quarter-2024-financial-results) ## [GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results March 26, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/280/gt-biopharma-reports-fourth-quarter-and-full-year-2023) ## [GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split February 1, 2024 ](https://ir.gtbiopharma.com/press-releases/detail/279/gt-biopharma-inc-announces-1-for-30-reverse-stock-split) ## [Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders December 6, 2023 ](https://ir.gtbiopharma.com/press-releases/detail/278/leading-proxy-advisory-firms-iss-and-glass-lewis)\n\n[ ![RSS](https://ir.stockpr.com/sandlandwaste/images/rssfeed.gif) ](https://ir.gtbiopharma.com/news/rss)\n\n  * 1\n  * [2](https://ir.gtbiopharma.com/press-releases?page=2)\n  * [3](https://ir.gtbiopharma.com/press-releases?page=3)\n  * [4](https://ir.gtbiopharma.com/press-releases?page=4)\n  * [5](https://ir.gtbiopharma.com/press-releases?page=5)\n  * [6](https://ir.gtbiopharma.com/press-releases?page=6)\n  * [7](https://ir.gtbiopharma.com/press-releases?page=7)\n  * [8](https://ir.gtbiopharma.com/press-releases?page=8)\n  * [9](https://ir.gtbiopharma.com/press-releases?page=9)\n  * [10](https://ir.gtbiopharma.com/press-releases?page=10)\n  * [...19](https://ir.gtbiopharma.com/press-releases?page=19)\n  * [Next » ](https://ir.gtbiopharma.com/press-releases?page=2)\n\n\n"
        },
        {
          "title": "IR Calendar",
          "url": "http://www.gtbiopharma.com/investors/news-events/ir-calendar",
          "content": "Nasdaq: GTBP\n\n#  [![GT Biopharma, Inc.](https://d1io3yog0oux5.cloudfront.net/_2c702d37748ae5a37d1e29db3f20fa7d/gtbiopharma/files/images/header-logo.png)](/)\n\n## IR Calendar\n\n  * [Home](/)\n  * [Investors](/investors)\n  * [News / Events](/investors/news-events)\n  * [IR Calendar](https://ir.gtbiopharma.com/ir-calendar)\n\n\n\n# IR Calendar\n\n## Upcoming Events\n\nThere are no upcoming events scheduled at this time. [Sign up here](https://ir.gtbiopharma.com/email-alerts) to receive notices about upcoming events and press releases.\n\n## Past Events\n\n###  Virtual KOL Event Showcasing \n\nOctober 10, 2024 • 12:00 pm \n\n[ Webcast](https://lifescievents.com/event/gtbiopharma/)\n\n###  3rd Annual ROTH Healthcare Opportunities Conference \n\nOctober 9, 2024 • 1:15 pm - 1:55 pm \n\n###  Annual Meeting of Stockholders \n\nJune 25, 2024 • 11:00 am \n\n[ Webcast](http://www.virtualshareholdermeeting.com/GTBP2024)\n\n[More past events »](https://ir.gtbiopharma.com/ir-calendar/archive)\n"
        }
      ]
    }
  ]
}